Artificial intelligence & machine learning
While drug discovery was an early target for AI capabilities, the technology’s predictive powers have made it a good fit for many other facets of the industry. As pharma leverages real-world uses of AI, the industry has also been careful about big-picture hype for the technology as some of its limitations become clear. INCLUDED IN […]
IoMT: Improving the Vitality of SMB Healthcare Companies with Better Connectivity
IoMT connects patients with their providers across the healthcare ecosystem, thus enabling care anywhere including remote patient monitoring and emerging hospital-at-home initiatives. Data shows that this trend is continuing among U.S. SMB healthcare companies. Discover the benefits and considerations of implementing IoMT solutions in this IDC whitepaper.
Compliant Content at Scale: AI & Process Innovation
While 80% are already adopting AI, medtech leaders also need to reconsider MLR processes. Moving beyond manual checks isn’t just about speed—it’s about scaling innovation without increasing risk. AI and process change can deliver immediate value including:
MLR Excellence as a Strategic Advantage
Medtech faces a critical operational challenge: commercializing products quickly while navigating medical, legal, and regulatory (MLR) teams. Due to the fundamental difference in product complexity, cross-functional stakeholder involvement, and regulatory requirements, adopting pharma models doesn’t work. Establishing MLR excellence in medtech is an evolution: moving from foundational governance and standardized workflows, to driving efficiency via […]
Real-World Lab Data: Precision in Commercialization & RWE
This infographic explores how real-world lab data is the essential source for precision across commercialization and real-world evidence generation. Effective commercial strategies require a foundation of data. Real-world lab data provides that foundation and generates compelling real-world evidence. The quantitative and qualitative results are critical for driving confident decision-making through the drug-development and commercialization life […]
The $13.4M Behavioral Health Gap Hiding in Your Health System
This ROI guide helps health system leaders put a real number on that cost and build the case for behavioral health investment. Untreated behavioral health impacts every line of business. Only 1 in 7 patients with behavioral health needs ever reaches appropriate care, and that gap doesn’t stay contained to behavioral health. It shows up […]
2026 Commercial Content Benchmark
The 2026 Veeva MedTech Commercial Content Benchmark Report, based on insights from more than 100 commercial and regulatory leaders across the U.S. and Europe, reveals a widening gap between growing content demand and the systems needed to support it. At the center of this gap is content operations: specifically the daily process of creating, reviewing, […]
Transform Your Healthcare Supply Chain with Zebra In A Box
Healthcare supply chains are under unprecedented pressure. Without real-time visibility, facilities face the costly consequences of misplaced inventory, stockouts, and compliance risks, all of which ultimately impact the quality of patient care. Our turnkey solution delivers: End-to-end traceability Faster replenishment Complete compliance Download the flyer to see how a connected supply chain can help eliminate […]
How the best HR leaders evaluate benefits
The women’s and family health benefits market has grown increasingly complex. All of the vendors are making the same promises about comprehensive solutions, large provider networks, and improved outcomes. Many employers believe they’re forced to make trade-offs: lower cost or better care, technology or human support, global scale or local expertise. In reality, those trade-offs […]
The Role of Societal Value Analyses in Supporting Access to Novel Pharmacotherapies in Asia-Pacific (APAC) Markets
As Asia-Pacific (APAC) markets grapple with rapidly aging populations and healthcare resource constraints, conventional budget impact and cost-effectiveness models often fall short in capturing the full picture of pharmaceutical innovation.